Dexcom (DXCM) Rating Reiterated by Piper Jaffray

Piper Jaffray reissued their buy rating on shares of Dexcom (NASDAQ:DXCM) in a research note published on Monday, March 12th.

A number of other brokerages also recently issued reports on DXCM. BidaskClub upgraded Dexcom from a hold rating to a buy rating in a research report on Friday, March 9th. ValuEngine downgraded Dexcom from a hold rating to a sell rating in a research report on Wednesday, March 7th. BMO Capital Markets raised their price target on Dexcom to $74.00 and gave the company an outperform rating in a research note on Tuesday, December 12th. Northland Securities lowered Dexcom from a market perform rating to an under perform rating and set a $85.00 price target on the stock. in a research note on Thursday, January 4th. Finally, Jefferies Group raised their price target on Dexcom from $58.00 to $70.00 and gave the company a buy rating in a research note on Friday, December 22nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $66.91.

How to Become a New Pot Stock Millionaire

DXCM traded down $2.13 during trading on Monday, reaching $70.15. 809,558 shares of the company traded hands, compared to its average volume of 1,301,305. Dexcom has a 12-month low of $42.62 and a 12-month high of $81.91. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.36 and a quick ratio of 5.04. The firm has a market cap of $6,277.71, a P/E ratio of -120.95 and a beta of -0.01.

Dexcom (NASDAQ:DXCM) last posted its earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. The firm had revenue of $221.00 million during the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. sell-side analysts anticipate that Dexcom will post -0.56 earnings per share for the current year.

In other news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total transaction of $568,600.00. Following the completion of the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Richard Doubleday sold 2,581 shares of the company’s stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $68.44, for a total value of $176,643.64. Following the transaction, the executive vice president now directly owns 94,429 shares of the company’s stock, valued at $6,462,720.76. The disclosure for this sale can be found here. Insiders sold 35,854 shares of company stock valued at $2,141,081 over the last three months. 1.70% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its position in shares of Dexcom by 3.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after purchasing an additional 8,171 shares in the last quarter. FDx Advisors Inc. increased its position in shares of Dexcom by 33.3% during the fourth quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock worth $1,324,000 after purchasing an additional 5,764 shares in the last quarter. Swiss National Bank increased its position in shares of Dexcom by 3.4% during the third quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock worth $15,578,000 after purchasing an additional 10,500 shares in the last quarter. Legal & General Group Plc increased its position in shares of Dexcom by 15.9% during the third quarter. Legal & General Group Plc now owns 95,757 shares of the medical device company’s stock worth $4,685,000 after purchasing an additional 13,166 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its position in shares of Dexcom by 169.7% during the third quarter. State of Wisconsin Investment Board now owns 184,765 shares of the medical device company’s stock worth $9,040,000 after purchasing an additional 116,254 shares in the last quarter.

WARNING: This article was first posted by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/04/06/dexcom-dxcm-given-buy-rating-at-piper-jaffray-companies/2037527.html.

About Dexcom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Analyst Recommendations for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.